PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Prior IV thrombolysis does not dictate first-line thrombectomy technique

alteplasetenecteplaseintravenous thrombolysismechanical thrombectomycontact aspirationstent retrieveracute ischaemic strokelarge vessel occlusionVECTOR trialsecondary analysisneurointervention Neurology / Neuropharmacology

Background Information

Does prior thrombolysis influence thrombectomy effectiveness in stroke recovery?

The impact of prior intravenous thrombolysis (IVT) on thrombectomy strategies for stroke remains uncertain, affecting clinical decision-making. In the VECTOR trial's secondary analysis, prior IVT did not significantly alter reperfusion success between thrombectomy strategies, though a slight advantage for contact aspiration (CA) was noted in non-IVT patients. Both contact aspiration and stent retriever plus contact aspiration are viable regardless of IVT use; findings are preliminary and specific to MRI-selected patients using alteplase. Prior IVT does not notably affect thrombectomy strategy outcomes, suggesting broad applicability of techniques.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Mouyal SJ, Maïer B, Labreuche J, Desilles JP, Mazighi M, Bourcier R, Redjem H

Citation: Mouyal SJ, Maïer B, Labreuche J, et al. Impact of prior intravenous thrombolysis on first-line thrombectomy strategy. A secondary analysis of the VECTOR trial. European stroke journal. 2026;11(7). doi:10.1093/esj/aakag087

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →